Skip to Content

RIMM introduces the BlackBerry Tour, a world phone for everyone

Text SizeAAA

Filed under: Company News, Earnings

More

Research in Motion Limited (RIMM) has crossed categories with its latest BlackBerry offering, the Tour. This new model is described as falling between the BlackBerry Curve and the BlackBerry Bold. The Bold targeted the high-end corporate BlackBerry user, while the Curve was aimed at the everyday consumer. The Tour goes after both.

RIMM's CEO Jim Balsillie said that the new device will launch with Verizon and Sprint in the United States and Telus and BCE's Bell in Canada.

Balsillie called the Tour a "big step forward," although it isn't drastically different from other BlackBerry offerings. The company calls the Tour a "world phone," as it can easily access voice and data services on networks outside the user's home country -- a popular option for business users. The retail market may be impressed with the multimedia features (including a photo and video camera, as well as a media player) offered by the Tour.

RIMM can't afford to alienate its corporate users, the main consumers of smartphones. And it seems that the company understands where its money comes from. That said, the main driver for the Tour is going to be price. As rivals like Apple and Palm use aggressive pricing to attract customers, RIMM will have to do the same if it wants to duplicate their success.

The company is set to report earnings later this week. The consensus estimate calls for 93 cents per share from the tech titan. A useful strategy ahead of earnings is to take a look at the company's technical performance and determine what could happen if the company tops or misses expectations.

Should earnings top expectations, the stock could enjoy a nice quick rally. There is little overhead resistance facing RIMM, although the shares have battled with the $80 region of late. Positive reaction to an earnings surprise could propel the stock through this resistance. Further north of the $80 region is the $95 level. Of course, this level is well north of the equity's current position, so there is time before it would come into play.

What about an earnings disappointment? If the shares need support, their 10-week moving average could step in and fill the roll. This trendline has ushered the stock higher since the end of March. With this trendline currently ascending through the $75 level, the underlying support isn't too far away. Theoretically, a technical examination of the stock suggests there is little downside to the stock, thanks to the underlying support.

Reader Comments (Page 1 of 1)

Interest Rates

5/1 ARM4.30%APR: 4.18%
30 Yr.
Fixed Mort.
5.13%APR: 5.29%
$30K
HELOC
8.13%APR: 0.00%
30 Mo
New Car Loan
7.05%APR: 0.00%
1 Yr. CD1.61%APR: 1.62%
DailyFinance Writers
Melly Alazraki Melly Alazraki Financial writer and analyst
Jeff Bercovici Jeff Bercovici Media columnist
Jonathan Berr Jonathan Berr Financial writer and media columnist
Mercedes Cardona Mercedes Cardona Retail reporter
Tim Catts Tim Catts Financial writer
Peter Cohan Peter Cohan Author, venture capitalist and financial writer
Carrie Coolidge Carrie Coolidge Financial writer
Lita Epstein Lita Epstein Financial writer
Sam Gustin Sam Gustin Technology Writer
Nikhil Hutheesing Nikhil Hutheesing Tech and investing editor
Joseph Lazzaro Joseph Lazzaro Markets and economics writer
Latif Lewis Michelle Leder Financial Columnist
Latif Lewis Latif Lewis Business news editor and management columnist
Anthony Massucci Anthony Massucci Senior writer and tech columnist
Doug McIntyre Doug McIntyre Business and investing news writer and editor
Michael Mercurio Michael Mercurio Managing Editor
Todd Pruzan Todd Pruzan Features editor
Michael Rainey Michael Rainey Editor and economics writer
Alex Salkever Alex Salkever Senior technology writer
David Schepp David Schepp Business News reporter
Matthew Scott Matthew Scott Investing reporter and editor
Dan Solin Daniel R. Solin Author, investment advisor and retirement expert
Amey Stone Amey Stone Executive editor
Bruce Watson Mark Svenvold Columnist, renewable energy
Russel Turk, M.D. Russell Turk, M.D. Healthcare policy columnist
Bruce Watson Bruce Watson Features Writer
my portfolios

Find out why more people track their portfolios on AOL Money & Finance than anywhere else.

Create a New Portfolio My Portfolios

Daily Finance Partners

More from the Weblogs Network